Funding
Opportunities
Directory
Search:
| Name | Deadline | Amount | Funder | Applicant | Purpose |
|---|---|---|---|---|---|
| PSC-CUNY Research Award Program | 2025-12-15 | $7,000+ | Professional Staff Congress-City University of New York (PSC-CUNY) | Early Career / Mid-Career |
Click for detailsCycle 57 of the PSC-CUNY Research Award Program is now active. The PSC-CUNY Research Award Program (“the Program”) seeks to grow faculty research, scholarship, and creative activities in all academically relevant disciplines. The Program is designed to strengthen both the CUNY research enterprise and the professional development of its faculty. Supported activities are expansive and may include diverse research forms and methods; efforts to start, continue, or finish a project; and/or pursuit of external grant awards. |
| Postdoctoral Fellowships | 2025-12-01 | $66,000+/yr for 3 years | American Cancer Society (ACS) | Postdoctoral |
Click for detailsPostdoctoral Fellowships (PF) support new investigators in research training programs to position them for independent careers in cancer research. As part of their evaluation, peer reviewers consider how well the fellowship will broaden the applicant's research training and experience. |
| RFA: Extramural Discovery Science Accelerator Award | 2025-12-01 | $75,000 | American Cancer Society (ACS) | Early Career / Mid-Career |
Click for detailsThe intent of the Extramural Discovery Science (EDS) Accelerator Award is to support the commercialization of an ongoing cancer research project and to validate and de-risk technologies. Proposals should address key experiment(s) required to move findings toward commercialization that do not easily fit into traditional grant funding mechanisms. This mechanism is not designed to initiate new projects or develop new directions for an ongoing project. The proposal should be commercially driven with the PI having a plan to license the technology, either to an established company or a start-up if the experiment(s) are successful. Examples of research that align with the focus of this funding initiative include but are not limited to: dosing, toxicity and/or efficacy testing; testing of biopsies or other patient samples to correlate clinical outcome; or technologies for healthcare delivery. Accelerator awardees will become part of an entrepreneurial collaborative learning community focused on technology commercialization. Grantees will have access to both educational programming developed by the ACS BrightEdge team and the team itself. |
| Small Business Transition Grant for New Entrepreneurs (R43/R44 Clinical Trial Required) | 2026-01-05 | varies to reflect the needs of the project | National Institutes of Health (NIH) | Small business |
Click for detailsThrough this Notice of Funding Opportunity (NOFO), the National Institutes of Health (NIH) and Centers for Disease Control and Prevention (CDC) aim to foster the advancement and accelerate the growth of early-career scientists transitioning to entrepreneurship by simultaneously supporting their entrepreneurial development and the conduct of research and development under their direction. This NOFO supports small business concerns (SBCs) in employing and developing researchers as entrepreneurial Program Directors/Principal Investigators (PDs/PIs). In addition to supporting research and development efforts at the SBC, a major component of this NOFO is entrepreneurial training, mentoring, and career development of the PD/PI. Optimal PDs/PIs for this award are scientists and professionals with research, technology development, and/or healthcare delivery skills and experience, but limited entrepreneurial and independent (non-mentored) research leadership experience. PDs/PIs are expected to grow their entrepreneurial skillset while working in a small business to develop promising technologies and products that align with NIH's or CDC’s missions to improve health and save lives. |
| The SWOG/Hope Impact Award Program | 2026-01-15 | $250,000 over 2 years | The Hope Foundation | Early Career / Mid-Career |
Click for detailsSWOG Cancer Research Network’s mission is to improve the practice of cancer medicine in preventing, detecting, and treating cancer, and to enhance the quality of life for cancer survivors, primarily through design and conduct of clinical trials. The SWOG/Hope Foundation Impact Award is a funding program from The Hope Foundation that encourages novel and innovative SWOG research by supporting early and conceptual stages of these projects. The work proposed should use resources from completed SWOG trials or be directly translatable to clinical trials in SWOG and the NCTN in the foreseeable future. |
| Improving Undergraduate STEM Education: Directorate for STEM Education (IUSE: EDU) | 2026-01-21 | $200,000+/yr up to 5 years | National Science Foundation (NSF) | Early Career / Mid-Career |
Click for detailsIUSE: EDU supports projects that seek to bring recent advances in STEM knowledge into undergraduate education, that adapt, improve, and incorporate evidence-based practices into STEM teaching and learning, and that lay the groundwork for institutional improvement in STEM education. In addition to innovative work at the frontier of STEM education, this program also encourages replication of research studies at different types of institutions and with different student bodies to produce deeper knowledge about the effectiveness and transferability of findings. IUSE: EDU also seeks to support projects that have high potential for broader societal impacts, including improved diversity of students and instructors participating in STEM education, professional development for instructors to ensure adoption of new and effective pedagogical techniques that meet the changing needs of students, and projects that promote institutional partnerships for collaborative research and development. The IUSE: EDU program features two tracks: (1) Engaged Student Learning and (2) Institutional and Community Transformation. |
| Cancer Research Education Grants Program-Courses for Skills Development (R25 Clinical Trial Not Allowed) | 2026-01-25 | $300,000/yr for 5 years | National Institutes of Health (NIH) | Early Career / Mid-Career |
Click for detailsThe NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this R25 program is to support educational activities that encourage individuals from diverse backgrounds, including those from groups underrepresented in the biomedical and behavioral sciences, to pursue further studies or careers in research. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on: courses for skills development. Applications are encouraged that propose innovative, state-of-the-art programs that address the cause, diagnosis, prevention, or treatment of cancer, rehabilitation from cancer, or the continuing care of cancer patients and the families of cancer patients, in order to advance the NCI mission. |
| Ruth L. Kirschstein National Research Service Award (NRSA) Institutional Research Training Grant (Parent T32) | 2026-01-25 | varies to reflect the needs of the project | National Institutes of Health (NIH) | Early Career / Mid-Career |
Click for detailsThe National Institutes of Health (NIH) will award Ruth L. Kirschstein National Research Service Award (NRSA) Institutional Research Training Grants (T32) to eligible, domestic institutions to develop and/or enhance predoctoral and postdoctoral research training, including short-term research training, to help ensure that a highly trained workforce is available to meet the needs of the Nation’s biomedical, behavioral, and clinical research agenda. Research training programs are expected to incorporate engaging, didactic, research, and career development elements to prepare trainees for careers that will have a significant impact on the health-related research needs of the Nation. Programs proposing only short-term predoctoral research training should not apply to this announcement, but rather to the Kirschstein-NRSA Short-Term Institutional Research Training Grant Program (T35) exclusively reserved for predoctoral, short-term research training. |
| Specialized Programs of Research Excellence (SPOREs) in Human Cancers for Years 2024, 2025, and 2026 (P50 Clinical Trial Required) | 2026-01-25 | $1,400,000/year for 5 years | National Institutes of Health (NIH) | Early Career / Mid-Career |
Click for detailsThrough this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) invites applications for P50 Research Center Grants for Specialized Programs of Research Excellence (SPORE). Based on the research proposed, applications may be jointly funded with the National Institute of Dental and Craniofacial Research (NIDCR). The program will fund P50 SPORE grants to support state-of-the-art investigator-initiated translational research that will contribute to improved prevention, early detection, diagnosis, and treatment of an organ-specific cancer or a highly related group of cancers. For the purpose of this NOFO, a group of highly related cancers are those that are derived from the same organ system, such as gastrointestinal, neuroendocrine, head and neck, and other cancers. Other programmatically appropriate groups of cancers may include those centered around a common biological mechanism critical for promoting tumorigenesis and/or cancer progression in organ sites that belong to different organ systems. For example, a SPORE may focus on cancers caused by the same infectious agent or cancers promoted and sustained by dysregulation of a common signaling pathway. In addition, a SPORE may focus on cross-cutting themes such as pediatric cancers or cancer health disparities. The research supported through this program must be translational and must stem from research on human biology using cellular, molecular, structural, biochemical, and/or genetic experimental approaches. SPORE projects must have the goal of reaching a translational human endpoint within the project period of the grant. |
| National Institute of General Medical Sciences Predoctoral Basic Biomedical Sciences Research Training Program (T32) | 2026-01-25 | varies to reflect the needs of the project | National Institutes of Health (NIH) | Mid-Career |
Click for detailsThe goal of the National Institute of General Medical Sciences (NIGMS) Ruth L. Kirschstein National Research Service Award (NRSA) Predoctoral Basic Biomedical Sciences Research Training Program is to develop a pool of well-trained scientists available to address the nation’s biomedical research agenda. Specifically, this funding announcement provides support to eligible, domestic organizations to develop and implement effective, evidence-informed approaches to biomedical graduate training and mentoring that will keep pace with the rapid evolution of the biomedical research enterprise. NIGMS expects that the proposed research training programs will incorporate didactic, research, and career development elements to prepare trainees for careers that will have a significant impact on the health-related research needs of the nation. |
| Biomedical Research Environment & Sponsored Programs Administration Development (BRE-SPAD) Program (UC2- Clinical Trial Not Allowed) | 2026-01-27 | $500,000/yr for 5 years | National Institutes of Health (NIH) | Mid-Career |
Click for detailsThe Biomedical Research Environment & Sponsored Programs Administration Development (BRE-SPAD) Program aims to support resource-limited institutions to conduct research, enhance their research environments, and increase sponsored programs administration capacity. |
| Stephen I. Katz Early Stage Investigator Research Project Grant (R01 Clinical Trial Not Allowed) | 2026-01-27 | varies to reflect the needs of the project | National Institutes of Health (NIH) | Early Career / Mid-Career |
Click for detailsThe Stephen I. Katz Early Stage Investigator Research Project Grant supports an innovative project that represents a change in research direction for an early stage investigator (ESI) and for which no preliminary data exist. Applications submitted to this notice of funding opportunity (NOFO) must not include preliminary data. Applications must include a separate attachment describing the change in research direction. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions. |
| EPSCoR Research Infrastructure Improvement Program: Focused EPSCoR Collaborations (FEC) | 2026-01-27 | $4,000,000+ over 4 years | National Science Foundation (NSF) | Early Career / Mid-Career |
Click for detailsThrough this program, NSF establishes partnerships with government, higher education, and industry that are designed to affect sustainable improvements in a jurisdiction's research infrastructure, Research and Development (R&D) capacity, and hence, its R&D competitiveness. The FEC program (formerly known as "EPSCoR Track-2 program") builds inter-jurisdictional collaborative teams of EPSCoR investigators in Science, Technology, Engineering, and Mathematics (STEM) focus areas consistent with the current National Science Foundation Strategic Plan. Projects are investigator-driven and must include researchers from at least two EPSCoR eligible jurisdictions with complementary expertise and resources necessary to address challenges, which neither party could address as well or as rapidly independently. FEC projects have a comprehensive and integrated vision to drive discovery and build sustainable STEM capacity that exemplifies institutional, geographic, and disciplinary diversity. The projects' STEM research and education activities seek to broaden participation through the strategic inclusion and integration of all individuals, institutions, and sectors. Additionally, EPSCoR recognizes that the development of early-career faculty is critical to sustaining and advancing research capacity. |
| Bioengineering Partnerships with Industry (U01 Clinical Trial Optional) | 2026-01-27 | varies to reflect the needs of the project | National Institutes of Health (NIH) | Early Career / Mid-Career |
Click for detailsThis Funding Opportunity Announcement (FOA) solicits applications from research partnerships formed by academic and industrial investigators to accelerate the development and adoption of promising bioengineering tools and technologies that can address important biomedical problems. The objectives are to establish these tools and technologies as robust, well-characterized solutions that fulfill an unmet need and are capable of enhancing our understanding of life science processes or the practice of medicine. Awards will focus on supporting multidisciplinary teams that apply an integrative, quantitative bioengineering approach to developing technologies. The goal of the program is to support technological innovations that deliver new capabilities which can realize meaningful solutions within 5 – 10 years. |
| RFA: Cancer Health Research Centers | 2026-02-01 | $4,070,000 over 4 years | American Cancer Society (ACS) | Early Career / Mid-Career |
Click for detailsAs part of the American Cancer Society (ACS) mission to promote fair and just opportunity to prevent, detect, treat, and survive cancer, ACS has created the Cancer Health Research Center (CHERC) program. CHERC's are designed to address cancer health inequities that affect local or regional communities. Priority will be given to Centers that present an integrated framework that focuses on actionable, solution-based research designed to improve the health of the community and advance our goals for achieving health equity and reducing cancer mortality. |
| Designing Synthetic Cells Beyond the Bounds of Evolution (Designer Cells) | 2026-02-01 | varies to reflect the needs of the project | National Science Foundation (NSF) | Early Career / Mid-Career |
Click for detailsBecause of recent technological advances in synthetic biology and bioengineering, researchers are now able to tailor cells and cell-like systems for a variety of basic and applied research purposes. The goal of this solicitation is to support research that (1) develops cell-like systems to identify the minimal requirements for the processes of life, (2) designs synthetically-modified cells to address fundamental questions in the evolution of life or to explore biological diversity beyond that which currently exists in nature, and (3) leverages basic research in cell design to build novel synthetic cell-like systems and cells for innovative biotechnology applications. Proposals submitted to this solicitation should address social, ethical, and safety issues associated with designing and building synthetically modified cells as an integrated component of the project. |
| Science and Technology Studies (STS) | 2026-02-02 | varies to reflect the needs of the project | National Science Foundation (NSF) | Early Career / Mid-Career |
Click for detailsScience and Technology Studies (STS) is an interdisciplinary field that investigates the conceptual foundations, historical developments and social contexts of science, technology, engineering and mathematics (STEM), including medical science. The STS program supports proposals across a broad spectrum of research that uses historical, philosophical and social scientific methods to investigate STEM theory and practice. STS research may be empirical or conceptual; specifically, it may focus on the intellectual, material or social facets of STEM. |
| Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01-Clinical Trial Not Allowed) | 2026-02-05 | $499,000/yr for 5 years | National Institutes of Health (NIH) | Early Career / Mid-Career |
Click for detailsThe purpose of this Notice of Funding Opportunity (NOFO) is to stimulate efforts to translate scientific discoveries and engineering developments into methods or tools that address problems in basic research to understand disease, or in applied research to assess risk, detect, prevent, diagnose, treat, and/or manage disease. The rationale is to deliver new capabilities to meet evolving requirements for technologies and methods relevant to the advance of research and delivery of care in pre-clinical, clinical and non-clinical settings, domestic or foreign, for conditions and diseases within the missions of participating institutes. |
| NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed) | 2026-02-05 | varies to reflect the needs of the project | National Institutes of Health (NIH) | Early Career / Mid-Career |
Click for detailsThis notice of funding opportunity (NOFO) encourages applications for research in cancer control and population sciences. The overarching goal is to provide support to promote research efforts on novel scientific ideas that have the potential to substantially advance cancer research in statistical and analytic methods, epidemiology, cancer survivorship, cancer-related behaviors and behavioral interventions, health care delivery, digital health and data science, and implementation science. |
| Modular R01s in Cancer Control and Population Sciences (R01 Clinical Trial Optional) | 2026-02-05 | $250,000/yr for 5 years | National Institutes of Health (NIH) | Early Career / Mid-Career |
Click for detailsThe NIH Research Project Grant supports a discrete, specified, circumscribed project in areas representing the specific interests and competencies of the investigator(s). The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions. |
| Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R01 Clinical Trial Not Allowed) | 2026-02-05 | $350,000/yr for 5 years | National Institutes of Health (NIH) | Early Career / Mid-Career |
Click for detailsThrough this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) along with other participating Institutes encourages submission of applications proposing to conduct secondary data analysis and integration of existing datasets and database resources, with the ultimate aim to elucidate cancer risk and related outcomes (e.g., risk prediction or reduction, survival, or response to treatment, etc.). The goal of this initiative is to address key scientific questions relevant to cancer by supporting the analysis of existing clinical, environmental, surveillance, health services, vital statistics, behavioral, lifestyle, genomic, and molecular profiles data. Applicants are encouraged to leverage and perform innovative analyses of the existing data. Applications may include new research aims that are being addressed with existing data, new or advanced methods of analyses, or novel combinations and integration of datasets that allow the exploration of important scientific questions in cancer research. This initiative is also available through the Exploratory/Developmental Research Grant (R21) mechanism. |
| Developing novel theory and methods for understanding the genetic architecture of complex human traits (R01 Clinical Trial Not Allowed) | 2026-02-05 | $500,000/yr for 5 years | National Institutes of Health (NIH) | Early Career / Mid-Career |
Click for detailsThe goal of this NOFO is to support applications for novel theory and methods development that enable better understanding of how genetic and non-genetic factors contribute to complex trait variation across individuals, families, and populations. Approaches should be interdisciplinary drawing from the natural and social sciences, account for interdependencies across scales of biological, social, and ecological organization, and make extensive use of theory, modeling, and validation with available large-scale datasets. |
| NLM Research Grants in Biomedical Informatics and Data Science (R01 Clinical Trial Optional) | 2026-02-05 | $250,000/yr for 4 years | National Institutes of Health (NIH) | Early Career / Mid-Career |
Click for detailsThe National Library of Medicine (NLM) supports innovative research and development in biomedical informatics and data science. This funding opportunity focuses on biomedical discovery and data-powered health, integrating streams of complex and interconnected research outputs that can be translated into scientific insights, clinical care, public health practices, and personal wellness. The scope of NLM's interest in these research domains is broad, with emphasis on new and innovative methods and approaches to foster data driven discovery in the biomedical and clinical health sciences as well as domain-independent, scalable, and reusable/reproducible approaches to discovery, curation, analysis, organization, and management of health-related digital objects. |
| Molecular Imaging of Inflammation in Cancer (R01 Clinical Trial Not Allowed) | 2026-02-05 | $500,000/yr for 5 years | National Institutes of Health (NIH) | Early Career / Mid-Career |
Click for detailsThrough this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) invites research grant applications (R01) for the development and application of current and emerging molecular imaging methods to gain fundamental insights into cancer inflammation in vivo. The motivation for this initiative is the recognition that much of the current imaging research on inflammation in cancer relies heavily on in vitro and ex vivo methods. These approaches have limited potential to provide significant insights into the dynamic interactions between cancer and inflammation. Utilizing molecular imaging probes in pre-clinical and clinical investigations allows for precise temporal resolution at molecular and cellular levels. This information is valuable for identifying and characterizing in vivo inflammatory cellular physiology in cancer and for detecting molecular changes in response to treatment. This NOFO encourages applications focused on developing integrated imaging approaches to investigate the role of inflammation in cancer through strong cross-discipline collaboration between cancer basic science researchers and imaging scientists. These collaborations are expected to advance the science and understanding of cancer inflammation interactions. |
| Investigator Initiated Innovation in Computational Genomics and Data Science (R01 Clinical Trial Not Allowed) | 2026-02-05 | $350,000/yr for 5 years | National Institutes of Health (NIH) | Early Career / Mid-Career |
Click for detailsThe purpose of this renewing Notice of Funding Opportunity (NOFO) is to support investigator-initiated research efforts fostering innovation in computational genomics, data science, statistics, bioinformatics, and data visualization and exploration. This NOFO supports development of innovative analytical methodologies and approaches and early-stage tools and software for genomics, rather than incremental advances or modification and application of existing approaches. Projects should be enabling for genomics research, broadly applicable to human health and disease, and generalizable across diseases and biological systems. This initiative is also available through the Exploratory/Developmental Research Grant (R21) mechanism. |
| The Role of Work in Health Disparities in the U.S. (R01 Clinical Trials Optional) | 2026-02-05 | varies to reflect the needs of the project | National Institutes of Health (NIH) | Early Career / Mid-Career |
Click for detailsThe purpose of this Notice of Funding Opportunity (NOFO) is to support innovative population-based research that can contribute to identifying and characterizing pathways and mechanisms through which work or occupation influences health outcomes and health status among populations with health and/or health care disparities. |
| Basic Research in Cancer Health Disparities (R01 Clinical Trial Not Allowed) | 2026-02-05 | varies to reflect the needs of the project | National Institutes of Health (NIH) | Early Career / Mid-Career |
Click for detailsThis Notice of Funding Opportunity (NOFO) encourages grant applications from investigators interested in conducting basic, mechanistic research into the biological/genetic causes of cancer health disparities. These research project grants (R01) will support innovative studies designed to investigate biological/genetic contributors of cancer health disparities, such as (1) mechanistic studies of biological factors associated with cancer health disparities, including those related to basic research in cancer biology or cancer prevention strategies, (2) the development and testing of new methodologies and models, and (3) secondary data analyses. This NOFO is also designed to aid and facilitate the growth of a nationwide cohort of scientists with a high level of basic research expertise in cancer health disparities research who can expand available resources and tools, such as biospecimens, patient derived models, and methods that are necessary to conduct basic research in cancer health disparities. |
| Assay development and screening for discovery of chemical probes, drugs or immunomodulators (R01 Clinical Trial Not Allowed) | 2026-02-05 | varies to reflect the needs of the project | National Institutes of Health (NIH) | Early Career / Mid-Career |
Click for detailsThrough this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) intends to stimulate research in discovery and development of novel, small molecules for cancer. Molecules discovered through this NOFO may be used to probe cancer biology, to validate cancer targets, or as the basis for optimized drugs. Stages of discovery research covered by this NOFO include: 1) development of the primary screen assay(s) and testing in an initial pilot screen; 2) primary screen implementation to identify initial screening hits (high throughput target-focused screens, or moderate throughput screens); 3) hit validation using a series of assays and initial medicinal chemistry inspection to prioritize the hit set. |
| Interventions to expand cancer screening and preventive services to ADVANCE health in populations that experience health disparities (R01, Clinical Trial Required) | 2026-02-05 | varies to reflect the needs of the project | National Institutes of Health (NIH) | Early Career / Mid-Career |
Click for detailsThe Office of Disease Prevention (ODP) and participating National Institutes of Health (NIH) Institutes, Centers, and Offices (ICs) are issuing this R01 to solicit applications to address barriers and facilitators that impede use or uptake of cancer screening and preventive services in populations that experience health disparities. Interventions should include screening, preventive services, or other healthcare processes, including timely follow-up of abnormal findings, and referral to accessible care. Projects are encouraged to leverage collaborations with community partners and service providers. Interventions should address barriers and facilitators at two or more of the following levels: patient, clinician, healthcare setting, and neighborhood/community. Specific research interests of participating NIH ICs are detailed within. |
| Interventions to Address Disparities in Liver Diseases and Liver Cancer (R01-Clinical Trials Optional) | 2026-02-05 | varies to reflect the needs of the project | National Institutes of Health (NIH) | Early Career / Mid-Career |
Click for detailsThis initiative will support multi-level and/or multi-domain intervention research to reduce disparities in liver diseases and liver cancer among populations who experience health disparities in the United States (U.S.). |
| Population Approaches to Reducing Alcohol-related Cancer Risk (R01 Clinical Trial Optional) | 2026-02-05 | varies to reflect the needs of the project | National Institutes of Health (NIH) | Early Career / Mid-Career |
Click for detailsThis Notice of Funding Opportunity (NOFO) aims to support research on interdisciplinary population approaches to increasing awareness of the relationship between alcohol and cancer risk, understanding and changing social norms related to alcohol consumption, developing and/or evaluating alcohol policy approaches, and the development, testing, and implementation of population-level interventions to reduce alcohol-related cancer risk. Applications that address multiple levels of consumption, such as moderate and heavy drinking, are of particular interest, as well as those focusing on alcohol use disorder (AUD) from the perspective of cancer prevention and control. Proposals addressing understudied areas are encouraged, as is attention to underrepresented minority (URM) populations experiencing cancer and alcohol-related disparities such as American Indian, and Alaskan Native populations. |
| Understanding Expectancies in Cancer Symptom Management (R01 Clinical Trial Required) | 2026-02-05 | varies to reflect the needs of the project | National Institutes of Health (NIH) | Early Career / Mid-Career |
Click for detailsThis Notice of Funding Opportunity (NOFO) will solicit mechanistic research that aims to understand how and why expectancy effects occur in a cancer context, elucidate their role in cancer symptom management, and identify patients, symptoms, cancer sites, and contexts in which expectancy effects can be leveraged to improve cancer outcomes. Expectancies are defined in this context as beliefs about future outcomes, including one’s response to cancer or cancer treatment. Expectancies can be evoked by social, psychological, environmental, and systemic factors. Expectancy effects are the cognitive, behavioral, and biological outcomes caused by expectancies. Expectancy effects can be generated by expectancies held by patients, clinicians, family members, caregivers, and/or dyadic/social networks. Program is particularly interested in applications that enroll individuals and groups from populations historically underrepresented or excluded from biomedical and behavioral research. |
| Utilizing the PLCO Biospecimens Resource to Bridge Gaps in Cancer Etiology and Early Detection Research (U01 Clinical Trial Not Allowed) | 2026-02-10 | varies to reflect the needs of the project | National Institutes of Health (NIH) | Early Career / Mid-Career |
Click for detailsThrough this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) encourages the submission of applications that propose to advance research in cancer etiology and early detection biomarkers, utilizing the advantages of the unique biorepository resources of the NCI-sponsored Prostate, Lung, Colorectal, and Ovarian Cancer (PLCO) Screening Trial. The PLCO Biorepository offers high-quality, prospectively collected, serial pre-diagnostic blood samples from the PLCO screened arm participants, and buccal cells from both the screened and the control arm participants. Available data associated with the biospecimens includes demographic, diet, lifestyle, smoking, screening results, and other clinical data. This NOFO supports a wide range of cancer research including, but not limited to, biochemical and genetic analyses of cancer risk, as well as discovery and validation of early detection biomarkers. The proposed research project must involve use of PLCO biospecimens and may include other resources; additionally, it should also take advantage of the unique characteristics of the PLCO biospecimens. Research on non-cancer outcomes, especially those related to aging (e.g., Alzheimer’s, depression, hip fracture, osteoporosis and rheumatoid arthritis) may also be supported. Research projects that do not involve the use of PLCO biospecimens will not be supported under this NOFO. |
| Independent Scientist Award (Parent K02-Independent Clinical Trial Not Allowed) | 2026-02-12 | varies to reflect the needs of the project | National Institutes of Health (NIH) | Early Career / Mid-Career |
Click for detailsThe purpose of the NIH Independent Scientist Award (K02) is to foster the development of outstanding scientists and enable them to expand their potential to make significant contributions to their field of research. The K02 award provides three to five years of salary support and "protected time" for newly independent scientists who can demonstrate the need for a period of intensive research focus as a means of enhancing their research careers. Each independent scientist career award program must be tailored to meet the individual needs of the candidate. |
| NIH Pathway to Independence Award (Parent K99/R00 Independent Clinical Trial Not Allowed) | 2026-02-12 | varies to reflect the needs of the project | National Institutes of Health (NIH) | Early Career |
Click for detailsThe purpose of the NIH Pathway to Independence Award (K99/R00) program is to facilitate a timely transition of outstanding postdoctoral researchers with a research and/or clinical doctorate degree from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NIH research support during this transition in order to help awardees to launch competitive, independent research careers. |
| Mentored Quantitative Research Development Award (Parent K25 Independent Clinical Trial Not Allowed) | 2026-02-12 | varies to reflect the needs of the project | National Institutes of Health (NIH) | Early Career / Mid-Career |
Click for detailsThe purpose of the NIH Independent Scientist Award (K02) is to foster the development of outstanding scientists and enable them to expand their potential to make significant contributions to their field of research. The K02 award provides three to five years of salary support and "protected time" for newly independent scientists who can demonstrate the need for a period of intensive research focus as a means of enhancing their research careers. Each independent scientist career award program must be tailored to meet the individual needs of the candidate. |
| Mentored Research Scientist Development Award (Parent K01-Independent Clinical Trial Not Allowed) | 2026-02-12 | varies to reflect the needs of the project | National Institutes of Health (NIH) | Early Career / Mid-Career |
Click for detailsThe purpose of the NIH Mentored Research Scientist Development Award (K01) is to provide support and “protected time” (three to five years) for an intensive, supervised career development experience in the biomedical, behavioral, or clinical sciences leading to research independence. Although all of the participating NIH Institutes and Centers (ICs) use this support mechanism to support career development experiences that lead to research independence, some ICs use the K01 award for individuals who propose to train in a new field or for individuals who have had a hiatus in their research career because of illness or pressing family circumstances. Other ICs use the K01 to support career development in specific fields. |
| Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH3 Clinical Trials Not Allowed) | 2026-02-13 | $250,000/yr for 3 years | National Institutes of Health (NIH) | Early Career / Mid-Career |
Click for detailsThrough this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) intends to accelerate the adoption and validation of molecular/cellular/imaging markers (referred to as "markers" or "biomarkers") and assays for cancer detection, diagnosis, prognosis, monitoring, and prediction of response or resistance to treatment, as well as markers for cancer prevention and control. This NOFO will also support the validation of pharmacodynamic markers and markers of toxicity. Applicants to this NOFO must have an assay(s) whose performance has been analytically validated in specimens similar to those for the intended clinical use of the marker(s) and assay(s). As chemotherapies and/or radiation therapies are increasingly combined with immunotherapies to enhance the durability of anti-cancer responses, assays for measuring multiple markers, including immune markers, can be developed and validated simultaneously. |
| Exploratory/Developmental Bioengineering Research Grants (EBRG) (R21 Clinical Trial Optional) | 2026-02-16 | $275,000 over 2 years | National Institutes of Health (NIH) | Early Career / Mid-Career |
Click for detailsThe purpose of this engineering-oriented funding opportunity announcement (FOA) is to encourage submissions of exploratory/developmental Bioengineering Research Grant (EBRG) applications to demonstrate feasibility and potential utility of new capabilities or improvements in quality, speed, efficacy, operability, costs, and/or accessibility of solutions to problems in basic biomedical, pre-clinical, or clinical research, clinical care delivery, or accessibility. This FOA will support clinical trials that test functionality or validate performance in the chosen setting. Applications that propose phase III clinical trials in any area of cancer research are not sought by and will not be supported through this FOA. |
| NIH Exploratory/Developmental Research Project Grant (Parent R21 Clinical Trial Not Allowed) | 2026-02-16 | $275,000 over 2 years | National Institutes of Health (NIH) | Early Career / Mid-Career |
Click for detailsThe NIH Exploratory/Developmental Grant supports exploratory and developmental research projects by providing support for the early and conceptual stages of these projects. These studies may involve considerable risk but may lead to a breakthrough in a particular area, or to the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on a field of biomedical, behavioral, or clinical research. |
| Exploratory Grants in Cancer Control (R21 Clinical Trial Optional) | 2026-02-16 | $275,000 over 2 years | National Institutes of Health (NIH) | Early Career / Mid-Career |
Click for detailsThrough this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) encourages the submission of exploratory/developmental research grant (R21) applications that focus on different aspects of cancer control by modifying behavior, screening, and understanding etiologic factors contributing to the development of cancer, and developing ways to control cancer. The overarching goal is to provide support to promote the early and conceptual stages of research efforts on novel scientific ideas that have the potential to substantially advance population-based cancer research, such as the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on a field of cancer research (e.g. epidemiologic, biomedical, behavioral, health care delivery or clinical). |
| Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R21 Clinical Trial Not Allowed) | 2026-02-16 | $275,000 over 2 years | National Institutes of Health (NIH) | Early Career / Mid-Career |
Click for detailsThrough this notice of funding opportunity (NOFO), the National Cancer Institute (NCI) invites applications for investigator-initiated studies addressing mechanisms by which incretin mimetics, specifically glucagon-like peptide (GLP)-1 or dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP)-1 receptor agonists (RAs), impact cancer risk. The focus on these agents is due to their reported effects on thyroid, prostate and other cancer risks, and the generally more favorable efficacy and side effect profile compared to other classes of incretin mimetics. In addition, this NOFO seeks to draw in talented scientists to the cancer biology field who may study incretin mimetic effects on diseases other than cancer. |
| Dissemination and Implementation Research in Health (R21 Clinical Trial Optional) | 2026-02-16 | $275,000 over 2 years | National Institutes of Health (NIH) | Early Career / Mid-Career |
Click for detailsThe purpose of this Notice of Funding Opportunity (NOFO) is to support studies that will identify, develop, and/or test strategies for overcoming barriers to the adoption, adaptation, integration, sustainability, scale-up, and spread of evidence-based interventions, practices, programs, tools, treatments, guidelines, and policies (herein referred to collectively as evidence-based interventions). Studies that promote the dissemination and implementation of evidence-based interventions among relevant communities are encouraged. Conversely, there is a benefit in understanding circumstances that create a need to stop or reduce (de-implement) the use of practices that are ineffective, unproven, low-value, or harmful. In addition, studies to advance dissemination and implementation research methods and measures are encouraged. Applications that focus on re-implementation of evidence-based health services that may be disrupted amidst disasters remain relevant. |
| Technology Development Research for Establishing Feasibility and Proof of Concept (R21-Clinical Trial Not Allowed) | 2026-02-16 | $275,000 over 2 years | National Institutes of Health (NIH) | Early Career / Mid-Career |
Click for detailsThis Notice of Funding Opportunity (NOFO)supports exploratory research leading to proof of concept for the development of new technologies relevant to the NIGMS mission. Projects should entail a high degree of risk and/or novelty, and have a high future potential impact in biomedical research. Outcomes or products of the proposed project, which should significantly advance the current state of the art, may include, but are not limited to: laboratory instruments and other devices, algorithms and software, chemical reagents and processes, biological molecules or systems that have been modified by human intervention for use as research tools. |
| Research Enhancement Award Program (REAP) for Health Professional Schools and Graduate Schools (R15 Clinical Trial Not Allowed) | 2026-02-25 | $375,000 over 3 years | National Institutes of Health (NIH) | Early Career / Mid-Career |
Click for detailsThe purpose of the Research Enhancement Award Program (REAP) for Health Professional Schools and Graduate Schools is to support small scale research grants at institutions that do not receive substantial funding from the NIH, with an emphasis on providing biomedical research experiences primarily for health professional, undergraduate and graduate students and enhancing the research environment at applicant institutions. |
| Academic Research Enhancement Award (AREA) for Undergraduate-Focused Institutions (R15 Clinical Trial Not Allowed) | 2026-02-25 | $300,000 over 3 years | National Institutes of Health (NIH) | Early Career / Mid-Career |
Click for detailsThe purpose of this Academic Research Enhancement Award (AREA) for Undergraduate-Focused Institutions is to support small scale research grants at institutions that do not receive substantial funding from the NIH, with an emphasis on providing biomedical research experiences primarily for undergraduate students, and enhancing the research environment at applicant institutions. |
| EHR Core Research (ECR): Building Capacity in STEM Education Research (ECR: BCSER) | 2026-02-27 | $25,000+ | National Science Foundation (NSF) | Early Career / Mid-Career |
Click for detailsECR’s Building Capacity in STEM Education Research (ECR: BCSER) supports projects that build investigators’ capacity to carry out high-quality STEM education research that will enhance the nation’s STEM education enterprise. In addition, ECR: BCSER seeks to broaden the pool of researchers who can advance knowledge regarding STEM learning and learning environments, broadening participation in STEM fields, and STEM workforce development. Researchers of races and ethnicities, genders, sexual orientations, and abilities who are currently underrepresented in their participation in STEM education research and the STEM workforce, as well as faculty at minority-serving and two-year institutions, are particularly encouraged to submit proposals. Specifically, ECR: BCSER supports activities that enable researchers to expand their areas of expertise and acquire the requisite knowledge and skills to conduct rigorous research in STEM education. Career development may be accomplished through investigator-initiated professional development and research projects or through institutes that enable researchers to integrate methodological strategies with theoretical and practical issues in STEM education. |
| NSF Scholarships in Science, Technology, Engineering, and Mathematics Program (S-STEM) | 2026-03-03 | $2,000,000+ over 6 years | National Science Foundation (NSF) | Early Career / Mid-Career |
Click for detailsThe main goal of the S-STEM program is to enable low-income students with academic ability, talent or potential to pursue successful careers in promising STEM fields. Ultimately, the S-STEM program seeks to increase the number of academically promising low-income students who graduate with a S-STEM eligible degree and contribute to the American innovation economy with their STEM knowledge. Recognizing that financial aid alone cannot increase retention and graduation in STEM, the program provides awards to institutions of higher education (IHEs) not only to fund scholarships, but also to adapt, implement, and study evidence-based curricular and co-curricular activities that have been shown to be effective supporting recruitment, retention, transfer (if appropriate), student success, academic/career pathways, and graduation in STEM. |
| International Research Scientist Development Award (IRSDA) (K01) Independent Clinical Trial Not Allowed | 2026-03-09 | varies to reflect the needs of the project | National Institutes of Health (NIH) | Early Career |
Click for detailsThe purpose of the International Research Scientist Development Award (IRSDA) is to provide support and protected time (three to five years) to advanced postdoctoral U.S. research scientists and recently-appointed U.S. junior faculty for an intensive, mentored research career development experience in a low- or middle-income country (LMIC), as defined by the World Bank, including "low-income," "lower-middle-income," and "upper-middle-income" countries) leading to an independently-funded research career focused on global health. This Notice of Funding Opportunity (NOFO) invites applications from postdoctoral research scientists and junior faculty from any health-related discipline who propose career development activities and a research project that is relevant to the health priorities of the LMIC under the mentorship of LMIC and U.S. mentors. |
| Solving the Early Detection and Early-Stage Diagnosis of Recalcitrant Cancers | 2026-03-10 | $2,000,000 over 2 years | American Association for Cancer Research (AACR), Lustgarten Foundation, & The Mark Foundation for Cancer Research | Early Career / Mid-Career |
Click for detailsCancer mortality rates have been steadily declining in the United States for several decades; however, certain types of cancer remain stubbornly lethal, with the lowest five-year survival rates. Effective screening tests are not available for many of these cancers, resulting in the late detection and diagnosis of advanced-stage malignancies for which there is a lack of available therapies with curative potential. The ability to detect and diagnose aggressive precursor lesions or early-stage cancers will be critical to ensuring long-term survival outcomes. Unfortunately, significant advances in early cancer detection and disease interception remain elusive. The projects funded through this initiative will advance our understanding of the origins and risk stratification of recalcitrant cancers and accelerate the development of technological and methodological innovation in early cancer detection and interception. It is recognized that significant barriers to the development and clinical implementation of early detection biomarkers exist, partly due to the need for rigorous testing within randomized clinical trials. Ideas that are broadly applicable to early detection across multiple cancer types are encouraged, including the development of novel clinical trial statistical methodologies that aim to assess the validity of early detection biomarkers. |
| NSF 25-548: Accelerating Research Translation (ART) | 2026-03-12 | varies to reflect the needs of the project | National Science Foundation (NSF) | Early Career / Mid-Career |
Click for detailsThe overarching goal for the Accelerating Research Translation (ART) program is to advance the U.S. scientific and economic leadership by building capacity and increasing the number of robust translational research ecosystems in Institutions of Higher Education (IHEs) that span across the full geography of our nation. The ART program framework is built around five distinct Tracks that are interconnected. These Tracks are differentiated by the RTRL. Track 1 is designed and intended for IHEs that currently have a low to medium RTRL. The IHEs responding to Track 1 are expected to have on-going research that has potential and opportunity for innovation translation but the infrastructure and the ecosystem for creating such opportunities for research translation are very limited. On the other hand, Track 2 is designed and intended for IHEs with some modest infrastructure and ecosystem that has a high volume of research but overall low level of research translation. Tracks 3 and 4 are designed and intended for IHEs or non-profits that have a significantly higher RTRL (or equivalent experience) and can create and deliver entrepreneurship-, technology transfer related education and training materials and offer related services to IHEs that have a much lower RTRL. Track 5 is designed and intended for providing support to an IHE that can coordinate research translation-related activities for teams across all the other Tracks. |
| BCCC-CURE/ACS Pilot Grants | 2026-03-15 | $40,000 | Brooklyn College Cancer Center (BCCC-CURE) | Early Career / Mid-Career |
Click for detailsThis one-year grant is open to full-time faculty at Brooklyn College within the first 6-years of initial appointment, or faculty transitioning to Cancer Research from related areas. Application deadline March 31st, 2026, 5:00PM |
| Dr. Charles A. Coltman, Jr. Fellowship Program | 2026-03-15 | $50,000/yr for 2 years | The Hope Foundation | Early Career |
Click for detailsA Career Development Program for Early Career Investigators-The primary purpose of the Dr. Charles A. Coltman, Jr. Fellowship is to engage outstanding early career investigators from SWOG-affiliated institutions in learning clinical trial methodology within an academic and network group environment that will lead to independent clinical research, while honoring the legacy of long-time SWOG Chair and leader, Dr. Charles A. Coltman, Jr. |
| Summer Research Education Experience Program (R25 Clinical Trial Not Allowed) | 2026-03-17 | $125,000/yr for 5 years | National Institutes of Health (NIH) | Early Career / Mid-Career |
Click for detailsThe NIH Research Education Program (R25) supports research educational activities that complement other formal training programs in the mission areas of the NIH Institutes and Centers. The overarching goals of the NIH R25 program are to: (1) complement and/or enhance the training of a workforce to meet the nation’s biomedical, behavioral and clinical research needs; (2) encourage individuals from diverse backgrounds, including those from groups underrepresented in the biomedical and behavioral sciences, to pursue further studies or careers in research; (3) help recruit individuals with specific specialty or disciplinary backgrounds to research careers in biomedical, behavioral and clinical sciences; and (4) foster a better understanding of biomedical, behavioral and clinical research and its implications. The overarching goal of this R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation’s biomedical, behavioral and clinical research needs. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on Research Experiences for high school students, undergraduate students, and/or science teachers during the summer academic break. |
| AHRQ Conference Grant Programs (R13) | 2026-04-12 | $50,000/yr up to 3 years | National Institutes of Health (NIH) | Early Career / Mid-Career |
Click for detailsThe Agency for Healthcare Research and Quality (AHRQ) announces its interest in supporting conferences through the AHRQ Single-Year and Multiple-Year Conference grant programs (R13). AHRQ seeks to support conferences that help further its mission to produce evidence to make health care safer, higher quality, more accessible, equitable and affordable, and to work with HHS and other partners to make sure the evidence is understood and used. |
| Environmental Health Sciences Core Centers Program (P30 Clinical Trials Optional) | 2026-04-20 | $850,000/yr up to 4 years | National Institutes of Health (NIH) | Early Career / Mid-Career |
Click for detailsThis Notice of Funding Opportunity (NOFO) invites grant applications for Environmental Health Sciences Core Centers (EHSCC). As intellectual hubs for environmental health science research, the EHSCC are expected to be the thought leaders for the field and advance the goals of the 2025-2029 NIEHS Strategic Plan. The Core Centers provide critical research infrastructure, shared facilities, services and/or resources, to groups of investigators conducting environmental health sciences research. An EHSCC enables researchers to conduct their independently-funded individual and/or collaborative research projects more efficiently and/or more effectively. The overall goal of an EHSCC is to identify and capitalize on emerging issues that advance improving the understanding of the relationships among environmental exposures, human biology, and disease. The EHSCC supports community engagement and translational research as key approaches to improving public health. |